LLS News Network

News and Information from The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society Launches National Patient Registr...

RYE BROOK, N.Y., Feb. 18, 2021 – The Leukemia & Lymphoma Society (LLS) announced today a collaboration with Ciitizen, a digital health technology startup, to collect data on the impact of COVID-19 and vaccination from people with a current or past diagnosis of blood cancer as part of a broader strategic partnership. The LLS National Patient Registry opened today to enroll all blood cancer patients, including th...

The Leukemia & Lymphoma Society Joins CURE Media Group's Strateg...

CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, survivors and caregivers, announces the addition of The Leukemia & Lymphoma Society (LLS) to its Strategic Alliance Partnership (SAP) program. “We are proud to be working with LLS and supporting them in their mission to support those affected by all blood canc...

Burlington Stores & its Customers Raise Nearly $4 Million for Th...

RYE BROOK, NY, February 10, 2021  – The Leukemia & Lymphoma Society (LLS), the global leader in the fight against blood cancer, and Burlington Stores, the national retailer delivering amazing deals to customers every time they shop, teamed up for the 19th consecutive year to raise critical funds to support LLS’s goal of creating a world without blood cancer, and to further their LLS Children’s Init...

FDA APPROVAL OF NEW CAR T-CELL THERAPY FURTHER SOLIDIFIES IMMUNOT...

Rye Brook, N.Y. (February 5, 2021) -- The U.S. Food and Drug Administration (FDA) today announced approval of a new CAR T-cell treatment for adult patients with certain forms of relapsed/refractory large B-cell lymphoma. With this latest approval, there are now four FDA-approved CAR T-cell therapies, and what was a brand-new approach introduced just three years ago, today is a mainstay in cancer care with scores...

NEW DRUG APPROVAL EXPANDS OPTIONS FOR PATIENTS WITH RARE MARGINAL...

Rye Brook, N.Y. (February 5, 2021) – The U.S. Food and Drug Administration (FDA) today announced approval of UKONIQ™ (umbralisib), a once-daily, oral medication for the treatment of marginal zone lymphoma (MZL) that has returned or worsened following prior treatment with an anti-CD20 antibody. MZL is a clinical heterogeneous, slow-growing non-hodgkin lymphoma composed of three subtypes: extranodal, nodal or splen...

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org.
An LLS representative will respond as soon as possible.